Lenalidomide/dexamethasone improves response and prolongs time to progression, even in patients with IgA multiple myeloma: A sub-analysis of the MM-009/010 studies

被引：4
|
作者：
Foa, Robert [1 ]
Weber, Donna [2 ]
Dimopoulos, Meletios [3 ]
Olesnyckyj, Marta [4 ]
Yu, Zhinuan [4 ]
Zeldis, Jerome [4 ]
Knight, Robert [4 ]
Chanan-Khan, Asher Alban [5 ]
机构：
[1] Univ Roma La Sapienza, Rome, Italy
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Athens, Sch Med, GR-11527 Athens, Greece
[4] Celgene Corp, Summit, NJ USA
[5] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4839.4839
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4839
引用
收藏
页码：284B / 284B
页数：1
相关论文
共 22 条
  • [1] ECOG performance status affects efficacy, but not safety, of lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (MM009/010 sub-analysis)
    Chanan-Khan, Asher A.
    Dimopoulos, Meletios
    Weber, Donna
    Olesnyekyj, Marta
    Yu, Zhinuan
    Zeldis, Jerome
    Knight, Robert
    San Miguel, Jesus F.
    BLOOD, 2007, 110 (11) : 799A - 799A
  • [2] Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis)
    Miguel, Jesus F. San
    Dimopoulos, Meletios
    Weber, Donna
    Olesnyckyj, Marta
    Yu, Zhinuan
    Zeldis, Jerome
    Night, Robert K.
    Raijkumar, Vincent
    BLOOD, 2007, 110 (11) : 796A - 796A
  • [3] Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (Mm): Analysis from MM-009 and MM-010 randomized phase III clinical trials.
    Chanan-Khan, Asher Alban
    Yu, Zhinuan
    Weber, Donna
    Chen, Christine
    Niesvizky, Ruben
    Spencer, Andrew
    Attal, Michel
    Belch, Andrew
    Prince, Miles
    Olesnyckyj, Marta
    Knight, Robert
    Zeldis, Jerome
    Dimopoulos, Meletius
    BLOOD, 2006, 108 (11) : 1015A - 1015A
  • [4] Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Chen, C.
    Spencer, A.
    Niesvizky, R.
    Attal, M.
    Stadtmauer, E. A.
    Petrucci, M. T.
    Yu, Z.
    Olesnyckyj, M.
    Zeldis, J. B.
    Knight, R. D.
    Weber, D. M.
    LEUKEMIA, 2009, 23 (11) : 2147 - 2152
  • [5] Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    C Chen
    A Spencer
    R Niesvizky
    M Attal
    E A Stadtmauer
    M T Petrucci
    Z Yu
    M Olesnyckyj
    J B Zeldis
    R D Knight
    D M Weber
    Leukemia, 2009, 23 : 2147 - 2152
  • [6] Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function.
    Weber, Donna
    Wang, Michael
    Chen, Christine
    Belch, Andrew
    Stadtmauer, Edward A.
    Niesvisky, Ruben
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome
    Knight, Robert D.
    Dimopoulos, Meletios
    BLOOD, 2006, 108 (11) : 1012A - 1013A
  • [7] CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF RESPONSE AND PROGRESSION-FREE SURVIVAL HAZARD RATIO OVER TIME
    Dimopoulos, M. A.
    Stewart, A. K.
    Wang, M.
    Maisnar, V.
    Minarik, J.
    Bensinger, W. I.
    Mateos, M. V.
    Ben-Yehuda, D.
    Kukreti, V.
    Obreja, M.
    Aggarwal, S.
    Moreau, P.
    Palumbo, A.
    HAEMATOLOGICA, 2016, 101 : 83 - 83
  • [8] Lenalidomide (L) in combination with dexamethasone (D) improves survival and time to progression in elderly patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM).
    Chanan-Khan, Asher Alban
    Weber, Donna
    Dimopoulos, Meletius
    Chen, Christine
    Niesvizky, Reuben
    Wang, Michael
    Belch, Andrew
    Attal, Michel
    Spencer, Andrew
    Prince, Miles
    Olesnyckyj, Marta
    Zeldis, Jerome
    Yu, Zhinuan
    Knight, Robert
    BLOOD, 2006, 108 (11) : 1014A - 1014A
  • [9] CARFILZOMIB AND LENALIDOMIDE AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: TEMPORARY ANALYSIS OF RESPONSE TO THE HAZARD RATIO FOR PROGRESSION-FREE SURVIVAL
    Maria Victoria, Mateos Manteca
    Meletios, Dimopoulos A.
    Keith, Stewart A.
    Michael, Wang
    Vladimir, Maisnar
    Jiri, Minarik
    William, Bensinger, I
    Dina, Ben-Yehuda
    Vishal, Kukreti
    Mihaela, Obreja
    Sanjay, Aggarwal
    Philippe, Moreau
    Antonio, Palumbo
    HAEMATOLOGICA, 2016, 101 : 27 - 27
  • [10] Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma
    Chanan-Khan, Asher A.
    Lonial, Sagar
    Weber, Donna
    Borrello, Ivan
    Foa, Robin
    Hellmann, Andrzej
    Dimopoulos, Meletios
    Swern, Arlene S.
    Knight, Robert
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (02) : 254 - 262
123